From 1000 Dollars to 150 Dollars Could the Golden Age of GLP-1 Drugs Be Ending
Last week, one remark from President Donald Trump sent shockwaves through the pharmaceutical sector. He suggested that the monthly cost of the weight-loss drug Ozempic could fall from roughly $1,000 to $150. The news immediately rattled investors, with shares of Novo Nordisk $NVOH and Eli Lilly $LLY both falling nearly 4% in pre-market trading.
Shortly after, Mehmet Oz , head of the U.S. Centers for Medicare and Medicaid Services, clarified that price negotiations are still ongoing and no agreement has been reached.
This is not just a momentary market blip. It represents the potential start of a profound shift in the GLP-1 drug market, which has been booming worldwide and considered a “trillion-dollar opportunity.”
The Policy Background and Why It Matters
GLP-1 drugs, including semaglutide and tirzepatide, have become global sensations. Originally developed to treat diabetes, they have also proven highly effective for weight loss. But the price tag is steep—over $1,000 a month in the U.S., even with insurance coverage for many patients.
Why is the U.S. government stepping in now? Nearly 40% of Americans are obese, and obesity is linked to serious cardiovascular and cerebrovascular risks. The cost of treating obesity-related illnesses is enormous. In 2023, Medicare and Medicaid spending totaled $1.56 trillion, accounting for more than a quarter of federal expenditures. Simply put, the government is under pressure to control health spending, and cutting drug prices is the most direct way to do it.
What the Market Could See
If these price reductions are implemented, the implications could be broad:
-
For pharmaceutical companies: Profit margins on high-cost drugs may shrink, forcing revenue expectations downward.
-
For insurers: Programs like UnitedHealth and Oscar Health could see reduced reimbursement pressures, easing some fiscal strain.
-
For health platforms: Companies like Hims & Hers Health may face reduced demand if patients can purchase cheaper drugs through alternative channels like “TrumpRx.”
-
For new drug launches: Eli Lilly and Novo Nordisk are actively developing oral weight-loss drugs to reach a broader market. A price reduction would likely force a rethink of pricing strategies for these new products.
In other words, this is more than just a price adjustment—it could reshape the entire weight-loss drug market.
The End of the Golden Age
The era of high profits and high prices for GLP-1 drugs may be coming to an end. While no final agreement has been reached, the policy trend is already attracting significant industry attention.
In the short term, if expensive weight-loss drugs are included in future negotiations, pharmaceutical companies’ revenue and profit forecasts will take a hit.
In the long term, competition will shift from price wars to a battle for comprehensive value, including:
-
Differentiated efficacy: weight loss combined with muscle gain or targeted therapies for different populations
-
Safety: minimizing side effects will be crucial
-
Sustained results: long-term weight maintenance matters more than short-term loss
-
Convenience: oral vs injectable drugs and ease of use will influence market adoption
Ultimately, the winners will be value creators, companies that balance efficacy, convenience, production costs, and global strategy. Patients, in turn, will benefit from a new era of value-driven weight-loss solutions: more effective drugs at lower prices.
My Take
The most important takeaway isn’t just short-term stock movements—it’s the structural shift in the market. The high-profit era may be ending, and future competition will favor companies that can deliver true value, not just high prices.
For investors, short-term volatility is manageable, but understanding long-term industry trends and structural changes is key to identifying opportunities and avoiding surprises.